Pancreatic cancer is a highly malignant tumour with an inferior prognosis. Current treatment methods have significant limitations of drug permeability and side effects. Recent studies have found that TRPM2 is highly expressed in pancreatic cancer cells. Based on this molecular characteristic, this study will aim to develop a targeted nano delivery system (TNP-TRPM2-Ab) that specifically targets TRPM2 for the delivery of the hydrophobic drug Trametinib. Through the covalent coupling of nanoparticles and antibodies, it is anticipated that precise recognition of cancer cells and controlled drug release will be achieved.

Chenyong Zhang. Development of TRPM2-Targeted Lipid Nanoparticle System for Delivery of Trametinib in Pancreatic Cancer. Academic Journal of Medicine & Health Sciences (2025), Vol. 6, Issue 9: 57-63. https://doi.org/10.25236/AJMHS.2025.060909.

[1] McGuigan, A. et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 24, 4846–4861 (2018).

[2] Lin, R. et al. TRPM2 promotes pancreatic cancer by PKC/MAPK pathway. Cell Death Dis. 12, 585 (2021).

[3] Chakkera, M., Foote, J. B., Farran, B. & Nagaraju, G. P. Breaking the stromal barrier in pancreatic cancer: Advances and challenges. Biochim. Biophys. Acta Rev. Cancer 1879, 189065 (2024).

[4] Greene, M. K. et al. Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells. Nanoscale 12, 11647–11658 (2020).

[5] Tang, H. et al. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma. BMC Cancer 23, 958 (2023).

[6] Hernández-Giottonini, K. Y. et al. PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. RSC Adv. 10, 4218–4231 (2020).

[7] Martínez Rivas, C. J. et al. Nanoprecipitation process: From encapsulation to drug delivery. Int. J. Pharm. 532, 66–81 (2017).

[8] Bhattacharjee, S. DLS and zeta potential - What they are and what they are not? J. Control. Release Off. J. Control. Release Soc. 235, 337–351 (2016).

[9] Malatesta, M. Transmission Electron Microscopy as a Powerful Tool to Investigate the Interaction of Nanoparticles with Subcellular Structures. Int. J. Mol. Sci. 22, 12789 (2021).

[10] Fuster, J. et al. HPLC-UV method development and validation for the quantification of ropinirole in new PLGA multiparticulate systems: Microspheres and nanoparticles. Int. J. Pharm. 491, 310–317 (2015).

[11] Gómez-Lázaro, L., Martín-Sabroso, C., Aparicio-Blanco, J. & Torres-Suárez, A. I. Assessment of In Vitro Release Testing Methods for Colloidal Drug Carriers: The Lack of Standardized Protocols. Pharmaceutics 16, 103 (2024).

[12] Lin, X., O’Reilly Beringhs, A. & Lu, X. Applications of Nanoparticle-Antibody Conjugates in Immunoassays and Tumor Imaging. AAPS J. 23, 43 (2021).

[13] Ferris, C., Casas, M., Lucero, M. J., de Paz, M. V. & Jiménez-Castellanos, M. R. Synthesis and characterization of a novel chitosan-N-acetyl-homocysteine thiolactone polymer using MES buffer. Carbohydr. Polym. 111, 125–132 (2014).

[14] Han, C. Y. et al. Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring. Nano Converg. 11, 53 (2024).

[15] Hueso, D., Fontecha, J. & Gómez-Cortés, P. Comparative study of the most commonly used methods for total protein determination in milk of different species and their ultrafiltration products. Front. Nutr. 9, 925565 (2022).

[16] Marques, A. C., Costa, P. C., Velho, S. & Amaral, M. H. Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles. Life Basel Switz. 14, 489 (2024).

[17] Luks, V. L. et al. Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells. PloS One 17, e0266218 (2022).

[18] Di Giorgio, E. et al. Photosensitization of pancreatic cancer cells by cationic alkyl-porphyrins in free form or engrafted into POPC liposomes: The relationship between delivery mode and mechanism of cell death. J. Photochem. Photobiol. B 231, 112449 (2022).

[19] Iyisan, B. et al. Antibody-Functionalized Carnauba Wax Nanoparticles to Target Breast Cancer Cells. ACS Appl. Bio Mater. 5, 622–629 (2022).

[20] Kenney, R. M., Loeser, A., Whitman, N. A. & Lockett, M. R. Paper-based Transwell assays: an inexpensive alternative to study cellular invasion. The Analyst 144, 206–211 (2018).

[21] Christensen, S. T. et al. MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats. PloS One 14, e0215398 (2019).

[22] Taylor, S. C. & Posch, A. The design of a quantitative western blot experiment. BioMed Res. Int. 2014, 361590 (2014).

[23] van Manen, L. et al. Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study. Biomolecules 13, 618 (2023).

[24] Moore, C. L., Savenka, A. V. & Basnakian, A. G. TUNEL Assay: A Powerful Tool for Kidney Injury Evaluation. Int. J. Mol. Sci. 22, 412 (2021).

[25] Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).

[26] Rotem, R., Prosperi, D. & Colombo, M. Chapter 10 - Targeted delivery of nanoparticles. in Frontiers of Nanoscience (eds Parak, W. J. & Feliu, N.) vol. 16 253–264 (Elsevier, 2020).

[27] Greene, M. K. et al. Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells. Nanoscale 12, 11647–11658 (2020).

[28] Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

[29] Pérez-Medina, C. et al. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 55, 1706–1711 (2014).